

Board of Commissioners Meeting

September 22, 2022 Summit Pacific Medical Center

Gravs HarborCounty Public Hospital District No.1

Agenda

1. 6:00 – Call to Order

- a. Introductions as needed
- b. Business from audience
- 2. 6:05 Consent Agenda See separate Consent Agenda Action (vote)

3. 6:o8- Approval of Minutes – Action (vote)

- a. August 25, 2022 Regular Meeting
- 4. 6:10 Patient Story Tori Bernier, CNO Info
- 5. 6:15 Population Health and Summit Care 3.0 Dr. Kevin Caserta and Jennifer Brackeen Info

6. Executive Reports

- a. 6:35 Quality Report and Dashboard, Tori Bernier Info
- b. 6:50 Finance Report, James Hansen Info
- c. 7:05 Advocacy Committee, Josh Martin (as needed)
- d. 7:10 Executive Report, Josh Martin Info

7. Commissioner Business

- a. 7:30 Medical Staff Privileges Action (vote)
 - *i.* Jessica Rydelski, ARNP- Emergency Medicine-Initial Appointment
 - ii. Georgi (Alex) Grekoff, MD- Emergency Medicine-Initial Appointment
 - iii. Ryan Richards, PA-C- Sleep Clinic-Initial Appointment
 - iv. Joel Stewart, PMHNP, Psychiatric Mental Health-Initial Appointment
 - v. Jennifer Theohairs, MD- Radiology- Initial Appointment
 - vi. Daniel Do-Dai, MD- Radiology- Initial Appointment
 - vii. Satish Kumar Cullath Harikkishnan, MD- Nocturnist (Hospitalist)-Initial Appointment
 - viii. Michael Magee, MD- Nocturnist (Hospitalist)-Initial Appointment
 - ix. Lauren Tada, DO- Nocturnist (Hospitalist)-Initial Appointment
 - x. Moshe Kovacgevich, MD- Nocturnist (Hospitalist)-Initial Appointment
 - xi. Thomas Lee, MD- Nocturnist (Hospitalist)-Initial Appointment
 - xii. Gavind Niamatali, MD- Nocturnist (Hospitalist)-Initial Appointment
 - xiii. John Zurasky, MD- Neurology-Re-Appointment
 - xiv. Ravi Menon, MD- Neurology-Re-Appointment
 - *xv.* Corey White, DO- Neurology-Re-Appointment
 - xvi. Tarvinder Singh, MD- Neurology-Re-Appointment
 - xvii. Biggya Sapkota, MD- Neurology-Re-Appointment
 - xviii. Ravi Pande, MD Neurology-Re-Appointment
 - xix. Margarita Oveian, MD- Neurology-Re-Appointment
 - xx. Aixa Espinosa-Morales, MD- Neurology-Re-Appointment
 - xxi. Nicholas Okon, DO- Neurology-Re-Appointment
- b. 7:40 USDA Preliminary Architectural Report– Info
- c. 7:50 "US Life Expectancy Declines" Hot Topic Discussion-Info
- d. 8:00 Upcoming Events, Andrew Hooper
- e. 8:05 Meeting Evaluation, Andrew Hooper

Josh Martin, Chief Executive Officer

600 E Main, Elma, WA 98541 • Ph. (360) 346-2222 Fax:(360) 346-2160

Owned and Operated by Grays Harbor County Public Hospital District No. 1



September 22, 2022 Summit Pacific Medical Center

Gravs HarborCounty Public Hospital District No.1

8. 8:10– Adjourn – Action (vote)

<u>Upcoming events</u>: - **BOLD events indicate desired Commissioner attendance.**

- Ladies Night Out | Wellness Center | October 6, 2022
- > WSHA Annual Member Meeting | Renton, WA | October 16-18, 2022

Consent Agenda

A very useful technique involves the use of a consent agenda. The board agenda planners (usually the executive or governance committee, but occasionally the board chair with the CEO) divide agenda issues into two groups of items. The first are those items that must be acted on because of legal, regulatory, or other requirements, but are not significant enough to warrant discussion by the full board. Such issues are combined into a single section of the board agenda book; members review these materials prior to the meeting, and if no one has any questions or concerns, the entire block of issues is approved with one board vote and no discussion. This frees up a tremendous amount of time that would otherwise be squandered on minor issues. Any member can request that an item be removed from the consent agenda and discussed by the full board. The success of the consent agenda is predicated upon all board members reading the material in the consent agenda section of the board agenda book. If they do not, then the board becomes a veritable rubber stamp. The second group of agenda items are those important issues that require discussion, deliberation, and action by the board. These are addressed one by one.

Executive Session Justification

Executive Session is convened to discuss the following topics, as permitted by the cited sections of the Revised Code of Washington (RCW):

- Executive session (RCW 42.30.110)
 - a. (a) national security
 - b. (b) (c)real estate
 - c. (d) negotiations of publicly bid contracts
 - d. (e) export trading
 - e. (f) complaints against public officers/employees
 - f. (g) qualifications of applicant or review performance of public employee/elective office
 - g. (h) evaluate qualifications of candidate for appointment to elective office
 - h. (i) discuss claims with legal counsel
 - *i.* existing or reasonably expected litigation
 - ii. litigation or legal risks expected to result in adverse legal or financial consequences
 - iii. presence of legal counsel alone does not justify executive session
 - i. QI/peer review committee documents and discussions
- Final action must be in open meeting



For the Period: August 2022

Description	Amount
Payroll	\$ 2,380,494
A/P Operations	\$ 3,650,210
A/P Capital	\$ 275,046
Community Care	\$ 235,135
Bad Debt	\$ 710,017
Property Tax Credit	\$ 966
Total	\$ 7,251,869



AGENDA	DISCUSSION/CONCLUSIONS	ACTIONS/FOLLOW-UP
CALL TO ORDER	CALL TO ORDER The meeting of the Board of Commissioners of the Grays Harbor County Public Hospital District No. 1 was called to order by Andrew Hooper at 6:00 pm Commissioners present: Andrew Hooper, Gary Thumser, Carolyn Wescott, Georgette Hiles Kevin Bossard	·,
	Present: Josh Martin, Jim Hansen, Tori Bernier, Jori Stott, Luke Zarecor, Anna Taylor (virtual), Justin Wozab (virtual), Lisa Carrell (virtual), Lourdes Schoch (virtual), Rachel Brown (virtual)	
CONSENT AGENDA	 Discussion regarding the \$ 4 million in operations during the month of July. The Finance Team will be providing detailed report next month. 	Commissioner Thumser made a motion to approve the Consent Agenda. Commissioner Wescott seconded the motion. All voted in favor.
APPROVAL OF MINUTES		Commissioner Hiles made a motion to approve the July 28, 2022 minutes. Commissioner Thumser seconded the motion. Commissioner Hiles amended motion to approve the July 28, 2022 minutes and the Strategic Planning Retreat minutes. All voted in favor.
BUSINESS FROM AUDIENCE	Business from Audience	
PATIENT STORY	CNO Bernier shared patient story (see patient story for more details).	
Audit PRESENTATION	CFO Hansen introduced founding partner of DZA Associates, Luke Zarecor.	



	August 25, 2022	
	 Luke Zarecor, Auditor gave presentation on the 2021 Financial Audit (see presentation and 2021 audit for more details). 	
	 Zarecor shared the Finance team did a fantastic job amidst COVID confusion. There was only one adjustment needed whereas similar organizations DZA has identified 20-30 corrections. 	
	 Days cash on hand is very healthy. 	
	 Zarecor reviewed the financial indicators. Similar hospitals were chosen to compare, however may not be of similar size. 	
	 Summit Pacific is overperforming in operating margin and proves to be a sustainable business model. 	
	 CFO Hansen shared the differentiation between the auditing data is 365 days vs the Finances team that uses 90 days. 	
	 Many patients used economic stimulus dollars to pay medical debt which improved bad debt recovery statewide. 	
	 Commissioner Hooper thanked Luke Zarecor for the presentation. CEO Martin thanked the Finance team for a great job! 	
TRANSPORT UPDATE	 CMO Dietrich provided an update on interfacility transports (see presentation for more details). Discussion regarding the remodel to the Maple Street House for the Olympic Ambulance group lease. 	
QUALITY	CNO Bernier shared that Quality Report and Dashboard (see report and dashboard for more details).	
	 There is an uptick in COVID numbers in our county although people seem to be not "as sick". 	
	 CDC has eased COVID requirements. Hospitals are waiting on the Governor to make announcements for state COVID requirements. 	
	 DOH came onsite for a focused survey for EMTALA complaint and Summit Pacific was found to be in compliance. 	
	 ACU continues to maintain positive patient experience scores even with a much higher volume. 	
	Physical therapy did great with their patient survey outcomes in July.	
	 There were zero (0) falls in July even with higher acuity and a higher census. Pharmacy has been doing a lot of work on rapid sequence intubation kits. 	
	 A new 340b vendor will launch early quarter four. 	
	There was one (1) employee injury in July. There was no lost time.	



	August 25, 2022
	 Karla De La Kruz is launching the speedy audit tool, a phone-based app to help with hand hygiene auditing.
FINANCE	 CFO Hansen presented the Finance Report (see report for more details). YTD actual margins are very strong for EBITDA, operating and net income. For the month of July, Summit Pacific was over budget due to high volumes. Total operating expense were above budget in July due to labor costs and 8-9% inflation. Georgette thanked CMO Dietrich and CFO Hansen for sending the GI letter for patient accounts that have not been billed. Inpatient days are up, and observations are back to normal. Ultrasounds were down in July because of a staffing issue. Commissioner Bossard questioned if Summit Pacific does heat mapping to identify where patients are coming from. Heat mapping is not a regular process, but has been used for special projects i.e. Master Facility Plan.
ADVOCACY	 Advocacy met this week to review federal, state, and local advocacy initiatives. This weekend some local community leaders have been invited to attend a dinner with Congressman Kilmer. CEO Martin and Commissioner Hiles will be attending Rural Advocacy Days in Washington DC the end of September. Summit Pacific and other hospitals are working with state legislators to address staffing and funding challenges. Summit Pacific will invite our legislators to come onsite. Dr. Dietrich was chosen to serve on the County Public Health Board. Summit Pacific has plans to do advocacy training with leaders in partnership with Jennifer Brackeen, Director of Care Innovation. CAM will be relaunching in January and will be incorporating participation from the Board, Blue Zones is still in need of an executive director for Grays Harbor County. Brenda Orffer will be serving as the community member on the Quality Committee.
EXECUTIVE REPORT	 CEO Martin reviewed the Executive Report (see report for more details). CEO Martin introduced Foundation recipient video (see video for more details) Dr. Teresa Lanier will be joining us as the ACU Medical Director early 2023. Congrats to Dr. Justin Taylor who was selected to serve on the Board of the Washington Association of Naturopathic Physicians Congrats Michael Fisher for being elected to the Washington Association of Nurse Anesthetists.



	August 25, 2022	
	 CNO Bernier provided an update on the Master Facility Plan (MFP) process. 	
	 The MFP Executive summary will be submitted to USDA. 	
	The Foundation Board did an annual strategic planning retreat facilitated by Tricia	
	Roscoe.	
	 Brad Thomas, Foundation Director will provide an update on Foundation Strategic 	
	Plan at a future meeting.	
	 Impact campaign for employees is closing tomorrow. The campaign well exceeded its goal and raised \$71,225. 	
	 Elma High School FFA leaders and ACENSUS both used our facilities for team 	
	building during the month of July.	
	 Summit care 3.0 is coming! Dr. Kevin Caserta and Jennifer Brackeen, Director of 	
	Care Innovation will give a presentation next month.	
COMMISSIONER	Medical Staff Privileges	Commissioner Hiles made
BUSINESS	 Sophia Liu, MD- Emergency Medicine – Initial Appointment 	motion to approve the Medical
	 Timothy Jan, DO – Radiology – Initial Appointment 	Staff privileges as presented.
	 Robert Rookstool, MD – Emergency Medicine - Initial Appointment 	Commissioner Thumser
	 Diane Brett, OT – Occupational Therapy – Initial Appointment 	seconded the motion. All voted
	 Jennifer Martin, PA – Emergency Medicine – Initial Appointment 	in favor.
	 James Wallace, MD -Emergency Medicine- Initial Appointment 	
	 Lindsey Brightman, DNP – Family Medicine -Initial Appointment 	
	 Udayan Srivastava, MD – Radiology – Initial Appointment 	
	 Jonathan Lee, MD – Radiology – Initial Appointment 	
	 Alexander Castiello, MD – Pathology – Initial Appointment 	
	 Olivia Nicholls, DPT – Physical Therapy – Initial Appointment 	
	 William Feldmann, MD – Radiology – Initial Appointment 	
	 Terra Grandmason, ARNP – Emergency Medicine- Secondary Privileges 	
	 Sean Cherry, PA – Emergency Medicine – Secondary Privileges 	
	 Janelle Wortman, PharmD – Pharmacy – Reappointment 	
	 Kishan Patel, MD – Neurology – Reappointment 	
	 Stephen Burton, MD – Neurology – Reappointment 	
	 Lilith Judd, MD – Neurology – Reappointment 	
	 George Lopez, MD – Neurology – Reappointment 	
	 Sheila Smith, MD – Neurology – Reappointment 	
	 Kyle Ogami, MD – Neurology – Reappointment 	



	August 25, 2022	
	 Joseph Freeburg, MD – Neurology – Reappointment David Alexader, MD – Radiology - Reappointment James Bell, MD – Radiology – Reappointment Mark Mayhle, MD – Radiology – Reappointment David Johnson, MD – Radiology – Reappointment Scott Vanderheiden, MD – Radiology – Reappointment Carter Yeatman, MD – Radiology – Reappointment Daniel Susanto, MD – Radiology – Reappointment Discussion was had regarding a secondary privilege. Secondary privileges are given to providers who may work in multiple areas. 	
	 Commissioner Hooper discussed purpose of surplus property resolutions. Surplus property resolutions happen regularly within the District to determine when items are no longer of value to the District can be either sold or destroyed. Hot topic discussion Discussion regarding "Why American teens are so sad." Discussion regarding he impacts of technology and social media to youth mental health. Discussion regarding the Behavioral Health Crisis meeting and the discussion around involving and belonging in our teens and kids and what we can do. Suggestion to have CMO Dietrich provide a community education event to discuss the impacts of technology to pediatric mental health. 	Commissioner Thumser made a motion to approve Resolution 2022-06 Surplus Property. Commissioner Bossard seconded the motion. All voted in favor.
	 Upcoming Events, Andrew Hooper Chairman Hooper reviewed upcoming events Donor appreciation event is August 31, 2022. Meeting Evaluation, Andrew Hooper Chairman Hooper facilitated meeting evaluation. Tobacco cessation as a future meeting topic. 	
EXECUTIVE SESSION	 Board Chair Hooper announced the Board will be going to executive session (RCW 42.30.110) (g) to review performance of a public employee. Board Chair Hooper announced the session was anticipated to last 10 minutes with no anticipated action. 	



	 The board recessed the session at 8:15 pm. The executive session convened at 8:20 pm. Chairman Hooper announced to the audience the addition of 5 minutes at 8:30 pm. The executive session ended at 8:35 pm. The regular session reconvened at 8:35 pm. 	
ADJOURNMENT	The regular session of the Board of Commissioner's meeting adjourned at 8:35 pm.	Commissioner Wescott made a motion to adjourn the meeting. Commissioner Hiles seconded the motion. All voted in favor.

Recording Secretary

Deorgette Hiles

Board Secretary

Financial Highlights – Monthly Dashboard

Summit Pacific Medical Center
Finance Dashboard
August 31, 2022
Key Financial Results used in review of Operational and Financial Performance

							Favorable	Variance = +	Unfavorable Variance = (
	August						Year-to-Date					
		Actual	Budget	Variance	Var%	Month	Actual	Budget	Variance	Var%	YTD	
Gross Operating Revenue	\$	13,655,478	\$11,537,607	\$ 2,117,871	18.4%		\$ 102,498,608	\$ 92,961,931	\$ 9,536,677	10.3%		
Total Operating Expenses	\$	5,647,818	\$ 4,976,476	\$ (671,343)	(13.5%)		\$ 39,428,967	\$ 38,357,180	\$(1,071,787)	(2.8%)	•	
Payment %		45.7%	45.5%	0.1%	0.1%	•	45.2%	45.0%		0.2%		
EBITDA Margin		13.5%	9.3%		4.2 %		20.6%	12.7%		7.9 %		
Operating Margin		7.0%	1.0%		6.0%		13.7%	4.3%		9.4%		
Net Income Margin		8.9%	2.5%		6.4%		15.8%	6.6%		9.2%		
Days in AR							52	47	(5)	(11.2%)		
рсон							265	260	5	1. 9 %		

2022 Income Statement

SUMMIT PACIFIC				A	uneb						Year-to-D	ate	·	
• MEDICAL CENTER •		Actual		Aug Budget	UST	Variance	Var%		Actual		Budget		. Variance	Var%
Gross Operating Revenue		Actour		bouger		vanance			Actour		Bouger		vanunce	VUI /o
Medicare Revenue	\$	5,558,570	\$	4,097,801	\$	1,460,768	35.6%	¢	41,204,274	\$	34,947,670	\$	6,256,604	17.9%
Medicaid Revenue	φ \$	3,582,855	Ք \$	3,637,055	•	(54,200)	(1.5%)		28,862,929	φ \$	28,092,409	.ս \$	770,520	2.7%
Other Revenue	Ψ \$	4,514,054	Ք \$	3,802,751	.₽ \$	711,303	18.7%		32,431,406	.թ \$	29,921,852	.ս \$	2,509,554	8.4%
Total Gross Operating Revenue	1	13,655,478		11,537,607		2,117,871	18.4%	1	102,498,608	_	92,961,931	₽ \$	9,536,677	<u> </u>
	Ş	13,055,470	Ş	11,557,607	Ş	2,117,071	10.4/0	Ş	102,470,000	Ş	72,701,731	Ş	7,550,077	10.376
Revenue Deductions														
Medicare Contractual	\$	3,346,274	\$	2,627,043	\$	(719,231)	(27.4%)	•	24,502,570	\$	22,484,470	\$	(2,018,100)	(9.0%)
Medicaid Contractual	\$	1,798,649	\$	2,074,003	\$	275,354	13.3%		15,966,364	\$	16,036,618	\$	70,254	0.4%
Other Contractual	\$	1,201,335	\$	1,047,658	\$	(153,676)	(14.7%)	•	10,187,094	\$		\$	(1,934,159)	(23.4%)
Bad Debt Expense	\$	767,207	\$	308,058	\$	(459,150)	(149.0%)		3,665,102	\$	2,487,164		(1,177,938)	(47.4%)
Community Care	\$	235,135	\$	167,375	\$	(67,761)	(40.5%)	•	1,288,267	\$	1,351,332		63,064	4.7%
Administrative Adjustments	\$	69,997	\$	60,731	\$	(9,266)	(15.3%)	-	529,075	\$	490,324		(38,752)	(7.9%)
Total Revenue Deductions	\$		\$		\$	(1,133,730)	(18.0%)				51,102,842			(9.9%)
Net Patient Revenue	\$	6,236,881	\$	5,252,740	\$	984,141	1 8.7 %	\$	46,360,135	\$	41,859,089	\$	4,501,046	10.8%
Other Revenue														
COVID Relief Income	\$	-	\$	-	\$	-	0.0%	\$	-	\$	-	\$	-	0.0%
Other Operating Income	\$	291,272	\$	235,222	\$	56,051	23.8%	•	3,319,950	\$	2,099,318	\$	1,220,632	58.1%
Total Other Revenue	\$		\$		\$	56,051	23.8%	<u> </u>	3,319,950	\$	2,099,318	\$	1,220,632	58.1%
Net Operating Revenue	\$	6,528,153	\$	5,487,961	\$	1,040,192	19.0%		49,680,085	\$	43,958,407	\$	5,721,678	13.0%
	Ŷ	0,010,100	Ý	0,-107,701	¥	1,0-10,172		¥	-17,000,000	Ŷ	10,100,407	Ŷ	5,. 21,070	
Operating Expenses	*	0.000.010	*	0.0/0.005	¢	47.4.1.1		¢	10,100,003	¢	01.045.010	¢	2 / / 5 222	1 4 007
Salaries & Wages	\$	2,393,813	\$	2,868,225	\$	474,411	16.5%		18,180,831	\$	21,845,913	\$	3,665,082	16.8%
Benefits	\$	605,330	\$	739,627	\$	134,296	18.2%		4,741,587	\$	5,629,634	•	888,047	15.8%
Professional Fees	\$	146,680	\$	25,705	\$	(120,975)	(470.6%)	•	756,350	\$	322,488	\$	(433,862)	(134.5%)
Supplies	\$	538,654	\$	414,603	\$	(124,051)	(29.9%)	•	3,066,378	\$	3,229,965	\$	163,588	5.1%
Utilities	\$	72,579	\$	43,918	\$	(28,661)	(65.3%)	•	383,435	\$	344,989		(38,446)	(11.1%)
Purchased Services	\$	1,568,368	\$	570,468	\$	(997,900)	(174.9%)		9,668,090	\$	4,472,365	\$	(5,195,725)	(116.2%)
Insurance	\$	45,758	\$	34,905	\$	(10,853)	(31.1%)	•	308,947	\$	279,240	\$	(29,707)	(10.6%)
Other Expenses	\$	195,250	\$	232,739	\$	37,489	16.1%	•		\$	1,832,096		(67,255)	(3.7%)
Rentals & Leases	\$	81,385	\$	46,287	\$	(35,098)	(75.8%)		423,998	\$	400,488	\$	(23,510)	(5.9%)
	^	5 / 47 010	~	4 07 4 47 4								~		(0.00)
Total Operating Expenses	\$	5,647,818	\$	4,976,476	\$	(671,343)	(13.5%)		39,428,967	\$	38,357,180			(2.8%)
	\$ \$	5,647,818 880,335	\$ \$		\$ \$	(671,343) 368,849	(13.5%) 72.1%		39,428,967 10,251,118	\$ \$	38,357,180 5,601,227	\$ \$	(1,071,787) 4,649,891	(2.8%) 83.0%
Total Operating Expenses EBITDA					-									
Total Operating Expenses	\$				-		72 .1%	\$				\$		
Total Operating Expenses EBITDA Interest & Depreciation Expenses		880,335	\$ \$	511,486	\$ \$	368,849		\$ \$	10,251,118	\$	5,601,227	\$	4,649,891	83.0%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest	\$ \$	880,335 143,426 279,972	\$ \$	511,486 143,426 312,776	\$ \$	368,849 (1)	72.1% (0.0%)	\$ \$ \$	10,251,118 1,155,899	\$ \$	5,601,227 1,155,896	\$ \$	4,649,891 (3)	83.0% (0.0%)
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses	\$ \$ \$ \$	880,335 143,426 279,972 423,399	\$ \$ \$ \$	511,486 143,426 312,776 456,201	\$ \$ \$ \$	368,849 (1) 32,803 32,803	72.1% (0.0%) 10.5% 7.2%	\$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955	\$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988	\$ \$ \$ \$	4,649,891 (3) 262,036 262,033	83.0% (0.0%) 10.3% 7.1%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss)	\$ \$ \$	880,335 143,426 279,972	\$ \$ \$	511,486 143,426 312,776	\$ \$ \$ \$	368,849 (1) 32,803	72.1% (0.0%) 10.5%	\$ \$ \$ \$	10,251,118 1,155,899 2,277,055	\$ \$ \$	5,601,227 1,155,896 2,539,092	\$ \$ \$	4,649,891 (3) 262,036	83.0% (0.0%) 10.3%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses)	\$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936	\$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284	\$ \$ \$ \$	(1) 32,803 32,803 401,652	72.1% (0.0%) 10.5% 7.2% 726.5%	\$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163	\$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239	\$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924	83.0% (0.0%) 10.3% 7.1% 257.7%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue	\$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348	\$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500	\$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0%	\$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147	\$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500	\$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses)	\$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736	\$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716	\$ \$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848 35,020	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9%	\$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888	\$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598	\$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710)	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%)
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Expenses Operating Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848 35,020 40,867	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848 35,020 40,867 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Expenses Operating Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848 35,020 40,867	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 401,652 5,848 35,020 40,867 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 13.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9,3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 13.5% 7.0%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9,3% 1.0%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 594.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 13.5% 7.0% 8.9%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9,3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 13.5% 7.0% 8.9% 52	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9,3% 1.0%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 594.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 13.5% 7.0% 8.9% 52 265	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9 ,3% 1.0% 2.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 4.2% 6.0% 6.4%	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 594.8% 254.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH Deduction %	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 13.5% 7.0% 8.9% 52 265 54.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9 ,3% 1.0% 2.5% 54.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 4.2% 6.0% 6.4%	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 594.8% 254.6% 0.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2% 0.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5% 0.4%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH Deduction % NPSR %	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 52 265 54,3% 45,7% 52 54,3% 45,7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 9 ,3% 1.0% 2.5% 54.5% 45.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 44.7% 594.8% 254.6% 0.3% 0.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6% 55.0% 45.0%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2% 0.2% 0.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5% 0.4%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH Deduction %	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 13.5% 7.0% 8.9% 52 265 54.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 9 ,3% 1.0% 2.5% 54.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 4.2% 6.0% 6.4%	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 594.8% 254.6% 0.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2% 0.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5% 0.4%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH Deduction % NPSR %	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 52 265 54,3% 45,7% 52 54,3% 45,7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 9 ,3% 1.0% 2.5% 54.5% 45.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 442,519	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 44.7% 594.8% 254.6% 0.3% 0.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6% 55.0% 45.0%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2% 0.2% 0.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5% 0.4%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Days in AR DCOH Deduction % NPSR % Net Operating Revenue %	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 13.5% 7.0% 8.9% 52 265 54.3% 45.7% 47.8%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 137,501 137,501 5 ,3% 1.0% 2.5% 54.5% 47,6%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	368,849 (1) 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 4.2% 6.0% 6.4% 0.1% 0.1% 0.2%	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 321.8% 321.8% 321.8% 254.6% 0.3% 0.3% 0.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2% 48.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6% 55.0% 45.0% 45.0% 47.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 4,936,861 7.9% 9.4% 9.2% 0.2% 0.2% 0.2% 1.2%	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 169.5% 138.5% 0.4% 0.4% 0.4% 2.5%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Net Income Margin Days in AR DCOH Deduction % NPSR % Net Operating Revenue % Benefits as a % Of SW Benefits as a % of SWB	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 580,020 54,3% 45,7% 45,7% 47,8% 25,3% 20.2%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 137,501 1 ,0% 2,5% 54,5% 45,5% 47,6% 25,8% 20,5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	368,849 (1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 4.2% 6.0% 6.4% 0.1% 0.2% 0.5% 0.3%	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 49.7% 321.8% 321.8% 321.8% 44.7% 594.8% 254.6% 0.3% 0.3% 0.3% 0.5% 1.9% 1.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2% 48.5% 26.1% 20.7%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 1,2.7% 4.3% 6.6% 55.0% 45.0% 47.3% 25.8% 20.5%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 2,2% 0.2% 0.2% 0.2% 0.2% 0.2% (0.3%) (0.2%)	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 169.5% 169.5% 169.5% 169.5% 169.5% 138.5% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Det Income Margin Days in AR DCOH Deduction % NPSR % Net Operating Revenue % Benefits as a % Of SW Benefits as a % of SWB Paid FTEs (excludes Agency)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 580,020 54,3% 45,7% 45,7% 47,8% 25,3% 20.2% 303,4		511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 9.3% 1.0% 2.5% 54.5% 45.5% 45.5% 47.6% 25.8% 20.5% 376.2	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 442,519 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.5% 0.3% 72.8	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 321.8% 321.8% 321.8% 321.8% 0.3% 0.3% 0.3% 0.5% 1.9% 1.5% 19.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2% 48.5% 26.1% 20.7% 293.01	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 1,2.7% 4.3% 6.6% 55.0% 45.0% 47.3% 25.8% 20.5% 371.1	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 2,2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 169.5% 169.5% 169.5% 138.5% 0.4% 0.4% 0.4% 0.4% 0.4% (1.2%) (1.0%) 21.0%
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Deduction % NPSR % Net Operating Revenue % Benefits as a % Of SW Benefits as a % of SWB Paid FTEs (excludes Agency) Salary per FTE	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 580,020 54,30% 45,7% 45,7% 45,7% 45,7% 265 54,3% 45,7% 47,8% 20,2% 303,4 7,890		511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 137,501 9,3% 1.0% 2.5% 54.5% 45.5% 47.6% 25.8% 20.5% 376.2 7,625	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 442,519 6.0% 6.4% 0.1% 0.1% 0.1% 0.2% 0.5% 0.3% 72.8 (265)	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 321.8% 321.8% 321.8% 321.8% 0.3% 0.3% 0.3% 0.5% 1.9% 1.5% 19.3% (3.5%)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2% 48.5% 26.1% 20.7% 293.01 62,048	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 12.7% 4.3% 6.6% 55.0% 45.0% 45.0% 47.3% 25.8% 20.5% 371.1 58,865	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 2,2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 61.9% 138.5% 61.9% 138.5% 0.4% 0.4% 2.5% (1.2%) (1.0%) 21.0% (5.4%)
Total Operating Expenses EBITDA Interest & Depreciation Expenses Interest Depreciation Total Interest & Depreciation Expenses Operating Income (Loss) Non-Operating Revenue/(Expenses) Tax Revenue Misc Revenue/(Expenses) Total Non-Operating Rev/(Expenses) Net Income (Loss) Net Income (Loss) w/out PPP+PRF METRICS EBITDA Margin Operating Margin Det Income Margin Days in AR DCOH Deduction % NPSR % Net Operating Revenue % Benefits as a % Of SW Benefits as a % of SWB Paid FTEs (excludes Agency)	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	880,335 143,426 279,972 423,399 456,936 13,348 109,736 123,084 580,020 580,020 580,020 580,020 54,3% 45,7% 45,7% 47,8% 25,3% 20.2% 303,4	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	511,486 143,426 312,776 456,201 55,284 7,500 74,716 82,216 137,501 137,501 137,501 9.3% 1.0% 2.5% 54.5% 45.5% 45.5% 47.6% 25.8% 20.5% 376.2	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	(1) 32,803 32,803 32,803 401,652 5,848 35,020 40,867 442,519 442,519 442,519 442,519 442,519 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.5% 0.3% 72.8	72.1% (0.0%) 10.5% 7.2% 726.5% 78.0% 46.9% 321.8% 321.8% 321.8% 321.8% 0.3% 0.3% 0.3% 0.5% 1.9% 1.5% 19.3%	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	10,251,118 1,155,899 2,277,055 3,432,955 6,818,163 598,147 432,888 1,031,035 7,849,198 7,849,198 20.6% 13.7% 15.8% 54.8% 45.2% 48.5% 26.1% 20.7% 293.01	\$\$ \$\$<	5,601,227 1,155,896 2,539,092 3,694,988 1,906,239 427,500 578,598 1,006,098 2,912,337 2,912,337 1,2.7% 4.3% 6.6% 55.0% 45.0% 47.3% 25.8% 20.5% 371.1	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	4,649,891 (3) 262,036 262,033 4,911,924 170,647 (145,710) 24,937 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 4,936,861 2,2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.	83.0% (0.0%) 10.3% 7.1% 257.7% 39.9% (25.2%) 2.5% 169.5% 169.5% 169.5% 169.5% 169.5% 138.5% 0.4% 0.4% 0.4% 0.4% 0.4% (1.2%) (1.0%) 21.0%



Balance Sheet as of August 2022

ASSETS	8/31/2022	7/31/2022	1 Month Variance	07/31/2021	12 Month Variance
Current Assets					
Operating Cash	48,857,314	49,235,981	(378,667)	40,520,841	8,336,473
Covid Cares Restricted	782,270	782,270	-	-	782,270
Debt Reserve	2,016,008	2,016,008	-	2,016,008	-
Accounts Receivables	22,743,248	22,514,653	228,597	18,841,547	3,901,701
Less Allow for Uncollectables	(4,382,006)	(4,241,624)	(140,382)	(3,169,062)	(1,212,944)
Less Contractual Adjustments	(9,495,380)	(9,932,457)	437,077	(7,771,202)	(1,724,178)
Accounts Receivable - Net	8,865,862	8,340,572	525,292	7,901,283	964,579
Taxes Receivable	29,608	37,210	(7,602)	27,978	1,630
Other Receivables	1,941,215	1,812,422	128,792	1,477,099	464,116
Inventory	781,626	776,441	5,185	569,712	211,914
Prepaid Expenses	1,015,977	687,726	328,252	607,917	408,061
Total Current Assets	64,289,880	63,688,630	601,253	53,120,837	11,169,043
Property, Plant and Equipment					
Land	1,652,029	1,652,029	-	1,652,029	-
Land Improvements	4,440,695	4,440,695	-	4,407,786	32,910
Buildings	43,842,103	43,842,103	-	43,387,314	454,789
Equipment	14,547,274	14,548,386	(1,112)	12,896,989	1,650,285
Construction In Progress	3,446,518	2,607,015	839,503	398,642	3,047,876
Less Accumulated Depreciation	(26,413,056)	(26,133,084)	(279,972)	(22,984,970)	(3,428,087)
Property, Plant and Equipment - Net	41,515,562	40,957,144	558,419	39,757,790	1,757,772
TOTAL ASSETS	105,805,443	104,645,773	1,159,671	92,878,627	12,926,816



Balance Sheet as of August 2022

LIABILITIES	08/31/2022	07/31/2022	1 Month Variance	07/31/2021	12 Month Variance
Current Liabilities					
Accounts Payable	2,059,386	1,651,046	408,340	786,109	1,273,277
Other Payables	776,704	773,860	2,844	295,410	481,294
Payroll and Related Liabilities	3,462,794	3,360,632	102,161	3,297,667	165,126
Interest Payable	191,317	142,465	48,852	197,852	(6,535)
Third Party Settlement Payable	(356,363)	(356,363)	-	811,525	(1,167,887)
Other Current Liabilities	1,838,452	1,776,330	62,122	5,272,780	(3,434,328)
Current Maturities of LTD	1,192,955	1,192,955	-	1,192,955	-
Total Current Liabilities	9,165,244	8,540,926	624,318	11,854,297	(2,689,053)
Non Current Liabilities					
Current Maturities of LTD	(1,192,955)	(1,192,955)	-	(1,192,955)	-
Long Term Debt	46,481,702	46,526,369	(44,667)	47,741,451	(1,259,749)
Total Non Current Liabilities	45,288,747	45,333,414	(44,667)	46,548,496	(1,259,749)
Total Liabilities	54,453,991	53,874,340	579,651	58,402,793	(3,948,802)
Net Assets					
Unrestricted Fund Balance	43,502,255	43,502,255	-	23,192,256.55	20,309,998
YTD Excess of Revenues	7,849,198	7,269,178	580,020	11,283,577.45	(3,434,379)
Total Net Assets	51,351,453	50,771,433	580,020	34,475,834	16,875,619
TOTAL LIABILITIES & NET ASSETS	105,805,443	104,645,773	1,159,671	92,878,627	12,926,816

2022	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	ост	NOV	DEC	
INPATIENT STATISTICS IP DISCHARGES	35	45	33	38	39	30	55	43					318
PRIOR	42	25	29	38	43	30	20	43 20	31	37	30	29	251
IP PATIENT DAYS	179	164	135	125	162	130	191	200					1,286
BUDGET PRIOR	177	153 97	128	132	166	159 144	133 109	135 122	122 110	143 129	124 85	122	1,183 1,025
IP EMERGENCY ADMITS	35	45	33	38	42	37	54	43	110	127	05	105	327
PRIOR	41	25	29	35	43	37	20	19	30	37	30	29	249
IP AVERAGE LENGTH OF STAY PRIOR	5.1 3.5	3.6 3.9	4.1 3.9	3.3 3.4	4.2 4.0	4.3 3.9	3.5 5.5	4.7 6.1	- 3.5	- 3.5	- 2.8	- 3.2	4.0
OUTPATIENT STATISTICS	5.5	5.7	5.7	5.4	4.0	5.7	5.5	0.1	5.5	5.5	2.0	5.2	4.1
OBSERVATION HOURS	751	1,428	1,892	1,219	1,302	5,433	869	835					13,729
PRIOR OBSERVATION STAYS	1,830 17	481 32	773 38	935 27	938 31	1,039 30	1,086 22	643 18	786	467	396	729	7,725
PRIOR	27	14	27	26	32	25	26	15	21	15	12	16	192
EMERGENCY DEPT VISITS	1,433	1,264	1,509	1,549	1,785	1,789	1,694	1,659					12,682
BUDGET PRIOR	1,153	947 957	1,190	1,269	1,457 1,487	1,411	1,489	1,444 1,461	1,475 1,474	1,437 1,450	1,375 1,350	1,353	10,360 10,425
MHC CLINIC VISITS	831	805	948	770	772	705	617	637	1,4/4	1,430	1,330	1,321	6,085
BUDGET	902	873	1,085	945	875	1,036	911	797	986	890	1,015	813	7,424
PRIOR	761	745	939	825	789	928	811	704	867	777	835	713	6,502
SPRES CLINIC VISITS BUDGET	160 133	150 124	257 105	224 174	205	201 118	379 224	311 320	364	294	294	204	1,887 1,344
PRIOR	61	57	48	80	66	49	56	55	105	127	127	93	472
SPMAT CLINIC VISITS	184	180	205	188	195	194	188	76	100	100	005	007	1,410
BUDGET PRIOR	205 203	204 203	249	221 218	188 186	227 224	228 218	192 190	198 198	198 207	205 192	237 233	1,714 1,674
SPWC CLINIC VISITS	2,935	2,832	2,977	2,509	2,679	2,629	2,733	2,870		207	172	200	22,164
BUDGET	2,369	2,396	2,377	2,444	2,759	2,906	2,969	2,932	3,079	3,083	3,125	3,131	21,152
PRIOR ALL CLINIC VISITS	2,833 4,110	2,534 3,967	3,162 4,387	2,885 3,691	2,745 3,851	2,981 3,729	2,986 3,917	3,376 3,894	3,066	3,364	3,165	3,053	23,502 31,546
BUDGET	3,609	3,597	3,816	3,784	3,968	4,287	4,332	4,241	4,627	4,465	4,639	4,385	31,546
PRIOR	3,626	3,289	4,067	3,711	3,630	4,190	4,075	4,308	4,191	4,368	3,916	3,842	30,896
PACC CLINIC VISITS PRIOR	4 6	5	6 9	7	2	2 6	11 5	1 7	14	9	4	2	31 46
	1,206	1.043	1,106	1,154	1,371	0 1,257	1,087	1,237	14	7	4	2	9,461
BUDGET	868	817	997	1,119	1,340	1,209	1,376	1,806	1,324	1,168	1,274	1,202	9,532
PRIOR	893	829	1,016	1,144	1,352	1,233	1,362	1,808	1,333	1,184	1,248	1,175	9,637
PACC + URGENT CARE VISITS BUDGET	1,210 874	1,048 821	1,112 1,006	1,155 1,126	1,372 1,342	1,259 1,215	1,098 1,381	1,238 1,813	1,338	1,177	1,278	1,204	9,492 9,578
PRIOR	899	833	1,025	1,151	1,354	1,239	1,367	1,815	1,347	1,193	1,252	1,177	9,683
ANCILLARY STATISTICS													
LAB BILLABLE TEST BUDGET	15,376 15,113	14,561 13,348	16,892 15,866	15,253 15,014	16,049 15,551	15,628 16,437	16,426 15,930	18,345 15,753	15,520	16,065	16,051	14,870	128,530 123,013
PRIOR	14,805	13,076	15,543	14,708	15,234	16,102	15,605	15,432	15,204	15,737	15,724	14,567	120,505
ALL XRAY EXAMS	1,371	1,391	1,495	1,390	1,553	1,530	1,333	1,419					11,482
BUDGET PRIOR	1,177	1,102	1,366	1,348	1,354	1,448 1,428	1,287	1,451 1,431	1,341 1,323	1,499 1,479	1,398 1,379	1,312	10,533 10,391
XRAY EXAMS	1,145	1,142	1,244	1,207	1,338	1,312	1,169	1,193	1,525	1,477	1,077	1,274	9,750
PRIOR	964	890	1,104	1,148	1,192	1,168	1,077	1,202	1,111	1,242	1,177	1,130	8,745
MAMMO EXAMS PRIOR	177	199 150	197 193	148	170 124	168 212	125 159	164 182	178	195	169	130	1,348 1,288
DXA EXAMS	49	50	54	35	45	50	39	62	./ 0	170	,	100	384
PRIOR	62	47	51	49	20	48	34	47	34	42	33	34	358
CT EXAMS BUDGET	504 512	455 401	562 516	529 510	596 536	553 529	592 542	638 524	486	555	520	478	4,429 4,071
PRIOR	476	373	479	474	498	492	504	487	452	516	483	444	3,783
ALL ULTRASOUND EXAMS	389	364	433	390	385	369	294	314					2,938
BUDGET PRIOR	309 304	316 311	357 352	342 337	338 333	383 377	385 379	390 384	330 325	412 406	355 350	337 332	2,819 2,777
ULTRASOUND EXAMS	304	311	352	337	333	377	239	261	525	400	330	332	2,777 2,489
PRIOR	265	274	309	302	289	328	327	332	301	349	299	290	2,426
	45	51	61	65	64	55	55	53	24	57	E 1	40	449
PRIOR MRI EXAMS	39 43	37 54	43 54	35 35	44 52	49 45	52 34	52 80	24	5/	51	42	351 397
BUDGET	98	87	108	108	87	101	87	131	114	84	107	35	810
PRIOR	56	50	62	62	50	58	50	75	65	48	61	20	463
THERAPY EXAMS		101	700	010		816	789	864					6,346
	709	626 834	790 994	863 860	889 835			873	98.5	931	9.51	779	7.033
BUDGET PRIOR		626 834 842	790 994 1,003	863 860 868	889 835 843	834 842	912 921	873 881	985 994	931 940	951 960	779 786	7,033 7,099
BUDGET PRIOR PT EXAMS-OUTPATIENT	709 891 899 648	834 842 566	994 1,003 698	860 868 778	835 843 785	834 842 713	912 921 658	881 723					7,099 5,569
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-INPATIENT	709 891 899 648 17	834 842 566 12	994 1,003 698 7	860 868 778 18	835 843 785 16	834 842 713 7	912 921 658 25	881 723 8					7,099 5,569 110
BUDGET PRIOR PT EXAMS-OUTPATIENT	709 891 899 648	834 842 566	994 1,003 698	860 868 778	835 843 785	834 842 713	912 921 658	881 723					7,099 5,569
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-INPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-OUTPATIENT	709 891 899 648 17 32 12 -	834 842 566 12 41 7 -	994 1,003 698 7 81 4 -	860 868 778 18 53 14 -	835 843 785 16 76 12 -	834 842 713 7 74 6 16	912 921 658 25 61 24 20	881 723 8 83 29 18					7,099 5,569 110 501 108 54
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-INPATIENT OT EXAMS-OUTPATIENT ST EXAMS-OUTPATIENT ST EXAMS-INPATIENT	709 891 899 648 17 32 12	834 842 566 12 41 7	994 1,003 698 7 81 4	860 868 778 18 53 14	835 843 785 16 76 12	834 842 713 7 74 6	912 921 658 25 61 24	881 723 8 83 29					7,099 5,569 110 501 108
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-INPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-OUTPATIENT	709 891 899 648 17 32 12 -	834 842 566 12 41 7 -	994 1,003 698 7 81 4 -	860 868 778 18 53 14 -	835 843 785 16 76 12 -	834 842 713 7 74 6 16	912 921 658 25 61 24 20	881 723 8 83 29 18					7,099 5,569 110 501 108 54
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-INPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL	709 891 899 648 17 32 12 - - 57 47	834 842 566 12 41 7 - - 5 6 47	994 1,003 698 7 81 4 - - 60 47	860 868 778 18 53 14 - - - 56 47	835 843 785 16 76 12 - - - 52 47	834 842 713 7 74 6 16 - - 50 47	912 921 658 25 61 24 20 1 1 53 47	881 723 8 8 83 29 18 3 3 52 47	994	940	960	786	7,099 5,569 110 501 108 54 4 54 54 47
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-INPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-INPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL PRIOR	709 891 899 648 17 32 - - - 57 47 53	834 842 566 12 41 7 - - 56 47 54	994 1,003 698 7 81 4 - - 60 47 52	860 868 778 18 53 14 - - 56 47 47	835 843 785 16 76 12 - - - 52 47 49	834 842 713 7 74 6 16 - - 50 47 52	912 921 658 25 61 24 20 1 1 53 47 57	881 723 8 8 83 29 18 3 3 52 47 52	994	940	960	786	7,099 5,569 110 501 108 54 4 4 54 4 54 47 59
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-INPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL	709 891 899 648 17 32 12 - - 57 47	834 842 566 12 41 7 - - 5 6 47	994 1,003 698 7 81 4 - - 60 47	860 868 778 18 53 14 - - - 56 47	835 843 785 16 76 12 - - - 52 47	834 842 713 7 74 6 16 - - 50 47	912 921 658 25 61 24 20 1 1 53 47	881 723 8 8 83 29 18 3 3 52 47	994	940	960	786	7,099 5,569 110 501 108 54 4 54 54 47
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT ST EXAMS-OUTPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL PRIOR DAYS CASH ON HAND GOAL PRIOR	709 891 899 648 17 32 - - 57 47 53 323 260 255	834 842 566 12 41 - - 56 47 54 328 260 256	994 1,003 698 7 81 4 - 60 47 52 307 260 262	860 868 778 18 53 14 - 56 47 47 47 47 281 260 254	835 843 785 16 76 12 - - 52 47 47 49 289 260 259	834 842 713 7 6 16 - - 50 47 52 287 280 257	912 921 658 25 61 24 20 1 53 47 57 277 260 249	881 723 8 83 29 18 3 3 52 47 52 265 260 249	994 	940 47 59	960 47 59	786 47 59	7,099 5,569 110 501 108 54 4 54 47 59 295 295 260 255
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT OT EXAMS-INPATIENT ST EXAMS-INPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL PRIOR DAYS CASH ON HAND GOAL PRIOR FTES TOTAL PAID	709 891 899 648 17 32 - - 57 47 53 323 260 255 285.5	834 842 566 12 41 7 - - 56 47 54 328 260 256 303.4	994 1,003 698 7 81 4 - - 60 47 52 307 260 262 305.1	860 868 778 18 53 14 - - 56 47 47 47 281 260 254 293.9	835 843 785 16 76 12 - - 52 47 49 289 260 259 294.2	834 842 713 7 74 6 16 - - 50 47 52 287 260 257 278.3	912 921 658 25 61 24 20 1 53 47 57 277 277 260 249 280.3	881 723 8 83 29 18 3 3 52 47 52 265 260 249 303.4	994 47 58 260 245	940 47 59 260	960 47 59 260	786 47 59 260 293	7,099 5,569 110 501 108 54 4 4 54 47 59 295 260 255 293.0
BUDGET PRIOR PT EXAMS-OUTPATIENT PT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT OT EXAMS-OUTPATIENT ST EXAMS-OUTPATIENT ST EXAMS-INPATIENT AR & CASH STATISTICS DAYS IN AR GOAL PRIOR DAYS CASH ON HAND GOAL PRIOR	709 891 899 648 17 32 - - 57 47 53 323 260 255	834 842 566 12 41 - - 56 47 54 328 260 256	994 1,003 698 7 81 4 - 60 47 52 307 260 262	860 868 778 18 53 14 - 56 47 47 47 47 281 260 254	835 843 785 16 76 12 - - 52 47 47 49 289 260 259	834 842 713 7 6 16 - - 50 47 52 287 280 257	912 921 658 25 61 24 20 1 1 53 47 57 277 260 249	881 723 8 83 29 18 3 3 52 47 52 265 260 249	994 47 58 260	940 47 59 260	960 47 59 260	786 47 59 260	7,099 5,569 110 501 108 54 4 54 47 59 295 295 260 255



Volume Dashboards





Finance Dashboards

